- Home
- RCUS vs CSWC Comparison
RCUS vs CSWC Comparison
Compare RCUS & CSWC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- CSWC
- Stock Information
- Founded
- RCUS 2015
- CSWC 1961
- Country
- RCUS United States
- CSWC United States
- Employees
- RCUS N/A
- CSWC N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- CSWC Textiles
- Sector
- RCUS Health Care
- CSWC Consumer Discretionary
- Exchange
- RCUS Nasdaq
- CSWC Nasdaq
- Market Cap
- RCUS 1.2B
- CSWC N/A
- IPO Year
- RCUS 2018
- CSWC N/A
- Fundamental
- Price
- RCUS $8.17
- CSWC $22.37
- Analyst Decision
- RCUS Strong Buy
- CSWC Hold
- Analyst Count
- RCUS 10
- CSWC 2
- Target Price
- RCUS $29.50
- CSWC $24.50
- AVG Volume (30 Days)
- RCUS 907.7K
- CSWC 593.3K
- Earning Date
- RCUS 05-07-2025
- CSWC 05-13-2025
- Dividend Yield
- RCUS N/A
- CSWC 11.44%
- EPS Growth
- RCUS N/A
- CSWC N/A
- EPS
- RCUS N/A
- CSWC 1.43
- Revenue
- RCUS $258,000,000.00
- CSWC $198,464,000.00
- Revenue This Year
- RCUS N/A
- CSWC $17.25
- Revenue Next Year
- RCUS $28.07
- CSWC $10.21
- P/E Ratio
- RCUS N/A
- CSWC $15.63
- Revenue Growth
- RCUS 120.51
- CSWC 17.51
- 52 Week Low
- RCUS $8.02
- CSWC $20.68
- 52 Week High
- RCUS $18.98
- CSWC $27.23
- Technical
- Relative Strength Index (RSI)
- RCUS 30.17
- CSWC 47.38
- Support Level
- RCUS $8.02
- CSWC $21.23
- Resistance Level
- RCUS $9.19
- CSWC $22.68
- Average True Range (ATR)
- RCUS 0.46
- CSWC 0.35
- MACD
- RCUS 0.01
- CSWC 0.05
- Stochastic Oscillator
- RCUS 7.46
- CSWC 70.81
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.